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Abstract
Background: Activin receptor 2 (ACVR2) is commonly mutated in microsatellite unstable (MSI) colon cancers, leading to
protein loss, signaling disruption, and larger tumors. Here, we examined activin signaling disruption in microsatellite stable
(MSS) colon cancers.
Methods: Fifty-one population-based MSS colon cancers were assessed for ACVR1, ACVR2 and pSMAD2 protein. Consensus
mutation-prone portions of ACVR2 were sequenced in primary cancers and all exons in colon cancer cell lines. Loss of
heterozygosity (LOH) was evaluated for ACVR2 and ACVR1, and ACVR2 promoter methylation by methylation-specific PCR
and bisulfite sequencing and chromosomal instability (CIN) phenotype via fluorescent LOH analysis of 3 duplicate markers.
ACVR2 promoter methylation and ACVR2 expression were assessed in colon cancer cell lines via qPCR and IP-Western blots.
Re-expression of ACVR2 after demethylation with 5-aza-29-deoxycytidine (5-Aza) was determined. An additional 26 MSS
colon cancers were assessed for ACVR2 loss and its mechanism, and ACVR2 loss in all tested cancers correlated with
clinicopathological criteria.
Results: Of 51 MSS colon tumors, 7(14%) lost ACVR2, 2 (4%) ACVR1, and 5(10%) pSMAD2 expression. No somatic ACVR2
mutations were detected. Loss of ACVR2 expression was associated with LOH at ACVR2 (p,0.001) and ACVR2 promoter
hypermethylation (p,0.05). ACVR2 LOH, but not promoter hypermethylation, correlated with CIN status. In colon cancer cell
lines with fully methylated ACVR2 promoter, loss of ACVR2 mRNA and protein expression was restored with 5-Aza treatment.
Loss of ACVR2 was associated with an increase in primary colon cancer volume (p,0.05).
Conclusions: Only a small percentage of MSS colon cancers lose expression of activin signaling members. ACVR2 loss occurs
through LOH and ACVR2 promoter hypermethylation, revealing distinct mechanisms for ACVR2 inactivation in both MSI and
MSS subtypes of colon cancer.
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Introduction
Colon cancers with high frequency microsatellite instability
(MSI-H) are associated with mutations in several genes with
coding repetitive sequences, such as transforming growth factor b
receptor 2 (TGFBR2) and activin type 2 receptor (ACVR2) [1–3].
Microsatellite stable (MSS) colon cancers have intact DNA
mismatch repair, but may harbor TGFBR2 kinase domain
mutations [4]. Other components of the TGFb canonical signaling
cascade, such as SMAD2 and SMAD4, are specifically inactivated
in a minority of colon cancers [5–7]. Systematic inactivation of
TGFb’s sister pathway, activin, has not been fully elucidated in
MSS colon cancers.
Activin is a member of the TGFb superfamily that regulates cell
differentiation in many tissues [8]. Similar to TGFb, activin
utilizes two cell surface receptors, activin receptor 1 (ACVR1) and
activin receptor 2 (ACVR2), followed by SMAD activation.
Another type 2 receptor, ACVR2B, cannot substitute for the
functions and signaling of ACVR2 [9].
ACVR2 was found mutated in the majority of MSI-H colorectal
cancers [10,11], primarily due to a frameshift in the A8 tract of
exon 10. Restoration of activin signaling and growth suppression
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8308occur in response to ACVR2 complementation in ACVR2-mutant
colon cancer cells [12,13]. We have previously demonstrated a
high frequency of ACVR2 mutations in MSI-H colon cancers in
conjunction with loss of ACVR2 protein expression [2] and
association with larger colon tumors and poorer histologic grade
[14]. Also, we found a subset of MSS colon cancers that lost
ACVR2 expression [2], akin to TGFBR2 loss found in MSS colon
cancers [4].
In this study, we explored activin signaling pathway disruption
and possible mechanisms in primary MSS colon cancer specimens
and colon cancer cells. We found that loss of ACVR2 expression
occurs in a subset of MSS tumors, which is often associated with
retained pSMAD2, the next downstream effector of both TGFb and
activin signaling. Unlike that of TGFBR2, ACVR2 loss in MSS
tumors occurs through a combination of LOH at ACVR2 and
distinct ACVR2 promoter methylation, but not genetic mutation. In
colon cancer cell lines, mechanisms for ACVR2 loss also segregate
according to microsatellite status, with MSI-H cell lines showing
ACVR2 polyadenine tract mutation and MSS colon cancer cells
demonstrating promoter hypermethylation. Thus we show that
disruption of activin signaling occurs in MSI and MSS colon cancers
by distinct mechanisms, revealing activin signaling as an important
target in the two most common genomic subtypes of colon cancer.
Results
Activin Signaling Pathway Members Are Targeted for
Inactivation in Subsets of Primary MSS Colon Cancers
Our previous data suggested at least partial loss of ACVR2
protein expression in a subset of primary MSS colon cancer
specimens despite wild type ACVR2 polyadenine tracts [2]. We
examined this further and sought to determine expression patterns
of both ACVR2, ACVR1 as well as its downstream effector,
pSMAD2, in 51 different primary colon cancer specimens with
microsatellite stable genomic backgrounds obtained from the same
cohort of the North Carolina Colon Cancer Study (NCCCS)
[15,16]. While ACVR1 receptor expression was lost in only 4%
(2/51) of the patient tumor specimens (Figure 1AB, top row),
loss of the primary receptor, ACVR2, occurred in 14% (7/51)
(Figure 1CD, middle row). Additionally, loss of pSMAD2
expression downstream of ACVR2 and ACVR1 activation by
activin occurred in 10% (5/51) of tested cases (Figure 1EF,
bottom row), and was commonly observed in tumors revealing
fully expressed receptors (Table 1).
All specimens with loss of at least one activin receptor pathway
component revealed expression of both total SMAD2 and
TGFBR2 (Table 1, Figure 2). These data suggest that ACVR2
protein loss has the greatest prevalence among MSS tumors,
followed by pSMAD2 loss, and then by ACVR1 loss. ACVR2 loss
and pSMAD2 loss appear to occur in complementary subgroups,
suggesting more than one target to inactivating activin signaling in
MSS colon cancers. Conversely, all MSS colon cancer specimens
with activin signaling component loss expressed TGFBR2.
LOH, but Not Mutation, Is Associated with Loss of ACVR2
Expression in Primary MSS Colon Cancer Specimens
To assess whether loss of receptor expression was due to loss of
heterozygosity (LOH), a common genomic mechanism of tumor
suppressor inactivation in MSS colon cancers, we assayed for
Figure 1. Loss of expression of three components of activin signaling in primary MSS colon cancers. Immunohistochemical analysis of
paraffin-embedded primary colon cancers assessed expression of target protein (brown) as compared to adjacent normal tissue. A and B (Top row):
ACVR1 expression is lost in a subset of MSS tumors. Example of tumor with expression in both normal and colon tumor tissue (left panel) and
selective loss in a subset of tumors, but not adjacent normal colonic tissue (right panel). Overall, ACVR1 loss was observed in 2/51 or 4% of all MSS
colon cancers analyzed. C and D (Middle row): ACVR2 expression is lost in a subset of MSS tumors. Two examples of selective loss of ACVR2 in colon
tumor, but not normal colonic tissue (left and right panel) are shown. Overall, ACVR2 loss was observed in 7/51 or 14% of all MSS colon cancers
analyzed. E and F (Bottom row): pSMAD2 expression is lost in a subset of MSS tumors. Example of expression in both normal and colon tumor tissue
(left panel) and selective loss in a subset of tumors, but not normal colonic tissue (right panel). Overall, pSMAD2 loss was observed in 5/51 or 10% of
all colon cancers analyzed.
doi:10.1371/journal.pone.0008308.g001
ACVR2 in MSS Colon Cancers
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assayed, 4 revealed allelic loss. LOH at ACVR2 was strongly
associated with loss of ACVR2 protein expression (p=0.006,
Fisher’s exact test), and 3/7 (43%) of MSS tumors with loss of
ACVR2 protein expression also showed LOH (Figure 2),
compared with 1/44 ACVR2 expressing tumors. No LOH was
found at the ACVR1 locus in either ACVR1 expressing or non-
expressing tumors. For further ACVR2 expression correlation
with LOH, we extended the number of patient tumors from 51 to
77 samples, which revealed 5 additional tumors with ACVR2
protein loss, bringing the total number to 12/77 or 16% (Table 2).
In this expanded group, 6/12 (50%) of MSS tumors with ACVR2
loss showed LOH (Table 2).
We then sequenced the coding microsatellite as well as 3
separate hot spots in the kinase domain of ACVR2 (akin to
corresponding mutations within TGFBR2 in MSS tumors)[4]. It
should be noted that the exon 10 A8 tract in ACVR2 lies in the
kinase domain of this receptor, and frameshift mutations as well as
other mutations in the kinase domain abolish the phosphorylating
capacity of ACVR2. However, we found no tumor specific
mutations corresponding with loss of ACVR2 protein expression.
These data suggest that other inactivating mechanisms play a role
in the loss of ACVR2 expression.
ACVR2 Promoter Hypermethylation Is Associated with
Loss of ACVR2 Expression in Primary MSS Colon Cancer
Specimens
To study whether epigenetic changes are associated with
ACVR2 expression loss, we assessed whether the ACVR2 promoter
was hypermethylated in colon cancer tissue as compared to
normal and if so, whether a specific methylation pattern of ACVR2
correlated with ACVR2 protein loss in primary MSS colon cancer
specimens. We initially divided the ACVR2 promoter into three
regions, region 1 (+142 to 2603), region 2 (2607 to 2958), and
Table 1. Composition of protein expression of activin
signaling proteins in colon cancers with loss of expression in
at least one pathway member.
ID ACVR1 ACVR2 TGFBR2 PSMAD2 SMAD2
MSS 884 absent present present present present
MSS 1026 present absent present present present
MSS 979 present absent present present present
MSS 1050 present absent present present present
MSS 1053 present absent present present present
MSS 796 present absent present present present
MSS 825 present absent present present present
MSS 1056 present present present absent present
MSS1052 present present present absent present
MSS 1004 present present present absent present
MSS 702 present present present absent present
MSS 994 absent absent present absent present
Two of the 51 tested MSS colon cancers lost ACVR1 protein expression, 7 lost
ACVR2 expression, and 5 lost pSMAD2 expression. While one cancer lost
expression of all three pathway components, the remaining 4 tumors with loss
of pSMAD2 expression showed expression in activin’s primary receptors, while
maintaining expression of total SMAD2 and TGFBR2, indicative that loss of
pSMAD2 may be a separate primary event. The remaining 39 primary MSS colon
cancers revealed no loss of activin signaling components.
doi:10.1371/journal.pone.0008308.t001
Figure 2. Summary of ACVR2 loss and its mechanisms in
primary MSS colon cancer specimens. Of the 51 MSS colon cancers
from the NCCCS cohort tested for ACVR2 and ACVR1 loss, 8 revealed
loss of either receptor (7 lost ACVR2 and 2 lost ACVR1 with one tumor
losing both, see Table 1). Of those 8, 1 lost pSMAD2. Of the 7 tumors
with ACVR2 loss, 3 revealed LOH and 3 had selective ACVR2 promoter
hypermethylation, while no mutations were found in any of the three
kinase domain hotspots or the coding polyadenine tract of exon 10,
commonly mutated in MSI colon tumors. Neither of the 2 tumors with
ACVR1 loss revealed LOH at the ACVR1 locus. Conversely, of the 43
tumors expressing both ACVR2 and ACVR1, 4 or 9% lost pSMAD2
expression, while maintaining total SMAD2 and TGFBR2 expression,
underscoring loss of SMAD2 phosphorylation capability as an additional
primary event to disrupt activin signaling.
doi:10.1371/journal.pone.0008308.g002
Table 2. Mechanisms of ACVR2 inactivation.
ID
ACVR2
Expression ACVR2 LOH
ACVR2
Methylation CIN
MSS 796 absent no LOH absent yes
MSS 825 absent no LOH absent yes
MSS 979 absent no LOH absent yes
MSS 994 absent no LOH present yes
MSS 1026 absent no LOH present no
MSS 1053 absent no LOH present no
MSS 747 absent LOH absent yes
MSS 427 absent LOH absent yes
MSS 345 absent LOH absent yes
MSS 1050 absent LOH absent yes
MSS 298 absent LOH absent yes
MSS 325 absent LOH absent yes
In the 12 total cancers with ACVR2 inactivation, 6 tumors revealed additional
LOH at the ACVR2 site, associated with CIN and 3 tumors revealed ACVR2
promoter hypermethylation associated with LOH-/MSI- phenotype. No
mutations in the kinase domain hotspots or coding polyadenine tract of ACVR2
were found, implicating a combination of LOH and ACVR2 promoter
hypermethylation in ACVR2 expression loss. For three tumors, no mechanism
for loss of ACVR2 expression was identified.
doi:10.1371/journal.pone.0008308.t002
ACVR2 in MSS Colon Cancers
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that there was no methylation in region 1 and minimal
methylation in region 2, but the 46 CpG dinucleotides between
to 2958 to 21484 nucleotides relative to the transcription start
site (region 3) (Figure 3A) were methylated in both cell lines and
clinical specimens (Figure 3B), but not corresponding adjacent
normal tissue (data not shown). Due to the difficulty in
amplification of larger amplicons from paraffin embedded tissue
DNA, we performed methylation specific bisulfite sequencing of a
slightly smaller region (2603 to 21297 positions) of the ACVR2
promoter in the clinical specimens.
In the ACVR2 non-expressing primary colon cancers from the
original sample size of 51 MSS tumors, 3/7 cancers demonstrated
complete methylation (100% methylated alleles) within region 3 of
the ACVR2 promoter, while none of the 13 ACVR2 expressing
primary colon cancers tissues assayed showed complete ACVR2
methylation, supporting a causative role for methylation and lack
of ACVR2 expression (p=0.03, Fisher’s exact test) (Table 2,
Figure 3B). Bisulfite sequencing results were consistent with the
MSP observations (data not shown), where 3/7 ACVR2-negative
CRCs showed the presence of specifically methylated alleles.
Although low levels of methylation (,50% methylated alleles)
were also found in 7/13 of the ACVR2-expressing CRCs, none of
the CRCs demonstrated complete methylation of any CpG
dinucleotides, which was consistent with enabling ACVR2
expression in these tumors (Figure 3B).
ACVR2 Promoter Hypermethylation Correlates with
ACVR2 Transcription and Protein Expression in Colon
Cancer Cell Lines
To corroborate our findings from clinical specimens in vitro,w e
assessed mechanisms of ACVR2 loss in colon cancer cells lines
based on microsatellite instability. We tested 3 MSI-H and 3 MSS
colon cancer cell lines for: 1) mutation in the coding polyadenine
tract of exon 10 of ACVR2,2 )ACVR2 promoter hypermethylation,
3) quantitative RT-PCR of ACVR2 mRNA, and 4) ACVR2
protein expression by immunoprecipitation. As previously report-
ed [2,12], biallelic mutation in the polyadenine tract of ACVR2 (A8
to A7) in the MSI-H colon cancer cell line HCT116 causes loss of
ACVR2 protein (Figure 3C and Table 3).
In the MSI-H cell lines SW48 and RKO, ACVR2 protein is
present, as it is in the MSS colon cancer cell lines CaCo2 and FET
(Figure 3C). Both RKO and SW48 contain a heterozygous
mutation at ACVR2, revealing wildtype A8 as well as mutant alleles
(Table 3). The A8 ACVR2 allele allows the expression of ACVR2
protein. The MSS colon cancer cell line HT29 expresses
decreased levels of ACVR2 mRNA and protein (Figure 3C, D
and E), unlike its MSS counterparts CaCo2 and FET, neither of
which harbor any exonic ACVR2 mutation (data not shown).
HT29 cells revealed a distinct ACVR2 promoter hypermethylation
pattern (Figure 3B) in association with mRNA and protein loss,
suggesting that this specific methylation pattern causes the loss of
ACVR2 expression. Demethylation of the ACVR2 promoter with 5-
Aza led to re-established expression of ACVR2 mRNA and
protein (Figure 3D and E). We performed an additional screen
of 11 colon cancer cell lines with either MSI (DLD1, HCA7,
HCT15, LoVo, LS174, SNU175, SNU407), or MSS (SNU81,
SNU503, SW480, and T84) backgrounds revealing similar levels
of ACVR2 mRNA and establishing HT29 as the only observed
MSS colon cancer model with distinct ACVR2 loss.
To correlate ACVR2 expression with tumor size, grade and
stage, we analyzed the expanded group of 77 tumors, which
contained 12 tumors with ACVR2 loss (Table 2). Of those, 69
had data on gender and race, 46 on tumor volume, 59 on tumor
stage, and 65 on grade (see Table 4) allowing subanalyses. Akin to
MSI-H colon cancers [14], loss of ACVR2 expression correlated
with larger tumors (p=0.024), while stage was unaffected when
compared to ACVR2-expressing tumors (Table 4). This parallels
our previous finding in MSI-H colon cancers, where loss of
ACVR2 protein was associated with larger, more poorly
differentiated tumors in a stage-independent fashion [14].
We then performed genomic subtype analysis of all ACVR2
non–expressing cancers and found that the lack of the chromo-
somal instability (CIN) phenotype correlated with ACVR2
promoter hypermethylation (Table 2), suggesting separate path-
ways for MSI-/LOH+ and MSI-/LOH- colon cancers.
Taken together, these data suggest that the clinico-pathologic
effects of ACVR2 protein loss may be similar in both MSI and MSS
colorectal cancers despite differing underlying mechanisms of loss,
implicatingACVR2lossasanimportantstepincoloncarcinogenesis.
Discussion
Disruption of activin signaling is common in MSI-H colon
cancer cell lines through mutation of ACVR2 in one of its
polyadenine tracts [10], causing loss of ACVR2 protein [2]. Loss
of ACVR2 protein expression was also noted in a small subset of
MSS colon cancers [2]. Here, we assessed the occurrence and
mechanism of disrupted activin signaling in MSS colon cancers
and demonstrate that activin signaling is targeted for disruption at
multiple levels in MSS colon tumors. Most commonly, ACVR2
expression is lost via a combination of LOH and epigenetic
silencing of the ACVR2 promoter. These findings underscore the
importance of abrogated activin signaling in colon tumorigenesis,
as its disruption occurs in both MSI and MSS subtypes of colon
cancer by differing distinct mechanisms.
In MSI-H colon cancers, both TGFb and activin are abrogated
due to frameshift mutations in the type II receptor [2,17]. The loss
of both of these signaling pathways may be beneficial for tumor
growth [12,18]. Both TGFb and activin use the same intracellular
SMAD proteins (SMAD 2 and 3) to transmit their signal. We
previously observed greater than 50% overlap between ACVR2
and TGFBR2 mutations in primary MSI colon tumors [2], possibly
because of additive effects in mediating the growth response,
which are currently under investigation.
It appears that in MSI colon cancers ACVR2 mutations may
occur early in tumorigenesis and are associated with increased
local growth [14]. In MSS colon cancers, loss of ACVR2
correlated with larger tumors, consistent with disruption of
activin-induced growth suppression. The timing of ACVR2
mutations in MSI colon cancer may be similar to that of TGFBR2
in which the frameshift mutations occur in high grade dysplasia at
the interface to malignancy [17].
We showthat in MSS colon cancers at least three members of the
activin signaling cascade, ACVR2, ACVR1, and pSMAD2 are
disrupted. A significant subset of colon tumors displayed a decrease
in phosphorylated SMAD with intact ACVR2 and TGFBR2,
indicating a separate primary event downstream of the primary
receptors. One case of loss of ACVR1, ACVR2 and pSMAD2 was
identified, which was TGFBR2 staining positive (Table 2). This
could be due to primary inactivation of pSMAD2 and separate
targeting of both activin receptors, or an IHC positive truncated
TGFBR2, leading pSMAD2 loss. The effect of loss of multiple
targets of the same signaling cascade still needs to be carefully
explored and suggests distinct functions of each member.
We detected LOH at the ACVR2 locus in 6% of MSS colon
tumors, increasing to 50% in tumors with loss of ACVR2 protein
expression. This overall rate is slightly lower than the frequency of
ACVR2 in MSS Colon Cancers
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ACVR2 promoter hypermethylation and loss of ACVR2 expression. A) ACVR2 promoter with map of positioning of MSP primers B) Using a
CpG islands search program, we identified the CpG islands within the ACVR2 promoter based upon following stringent criteria: ,CG
percentage.55%; observed CpG/expected CpG .0.65; length .500 bp. All CpG dinucleotide sequences are represented by vertical bars across the
horizontal line depicting the promoter sequence. Each circle in the bottom panel illustrates an individual CpG site corresponding to the vertical bars
depicted in the upper panel. Based upon bisulfite sequencing, each CpG site was scored quantitatively as 100% methylated (dark circles), .50%
methylated (dark grey circles), ,50% methylated (light grey circles) or unmethylated (white circles). As indicated, 3 of 7 ACVR2-negative CRCs
demonstrated complete methylation of the critical region of ACVR2 promoter, while none of the ACVR2-expressing tumors showed any evidence for
high degree/complete methylation of ACVR2 promoter. A methylation pattern similar to that seen in ACVR2 negative colon cancers was observed in
the MSS colon cancer cell line HT29 with genomic DNA from HT-29 allowing for sequencing of a slightly larger region of the ACVR2 promoter. C) Six
colon cancer cell lines with different microsatellite instability backgrounds (see Table 3) were analyzed for ACVR2 protein expression using
immunoprecipitation techniques. Two cell lines, HCT116 (an MSI colon cancer cell line with biallelic frameshift mutations in ACVR2) and the MSS colon
cancer cell line HT29 (with ACVR2 promoter hypermethylation), revealed loss of ACVR2 protein expression. D) Loss of ACVR2 protein expression
correlated with decrease in ACVR2 mRNA transcription via quantitative PCR in HT29 cells when compared to the ACVR2 expressing cell line FET using
GAPDH for standardization. This experiment was performed three times in triplicates, and the bar graph represents one experiment with * indicating
a statistically significant difference with a p,0.001. E) ACVR2 protein expression was re-established following demethylation treatment with 59Aza.
doi:10.1371/journal.pone.0008308.g003
ACVR2 in MSS Colon Cancers
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ACVR2 status [19], although we have previously observed cohort-
dependent frequencies for ACVR2 expression that may be stage
or race-dependent [14].
Our mutational analysis focused on hotspots akin to those
implicated in inactivation of the TGFBR2 kinase domain
inactivation [4], but we did not find any tumor-associated
mutations when sequencing all exons in ACVR2 expressing and
non-expressing colon cancer cell lines. It is possible that mutations
outside of the hotspots may contribute to loss of ACVR2 in
primary colon cancer specimens, although in light of the evidence
for LOH as well as epigenetic silencing, this is likely to be a less
important tumorigenic mechanism. However, it may play a role in
the three tumors with loss of ACVR2 where we found no genetic
or epigenetic mechanism directly explaining that loss.
This is the first report describing ACVR2 loss in MSS colon
cancers and ACVR2 promoter hypermethylation as a mechanism,
and contrasts with the mechanisms of ACVR2 loss in the MSI colon
cancer cells [12]. In both primary MSS colon tumors and in HT29
colon cancer cells, the region of promoter hypermethylation that is
associated with loss of ACVR2 expression is between nucleotides
21297 to 2958. Among genes that are targets for epigenetic
silencing,hMLH1 is the best studied for methylation, and it hasbeen
proposed that the promoter region adjacent to the transcription
start site (TSS) is critical for transcriptional silencing of this gene
[20]. There is lack of similar data for most other genes, but hMLH1
promoter region data is often used as a paradigm, and it is believed
thatformostgenes,analysisofasimilarpromoterregioniscriticalto
correlate DNA methylation findings with loss of gene expression. In
this study, we have analyzed .1500 bp proximal to the TSS, and
found good correlation between ACVR2 promoter methylation (in
regions2958to21297)andloss ofproteinexpression byIHC.Our
data suggests that instead of mere proximity to the TSS, differential
access to methylation co-activators or repressors in a promoter
determines gene silencing, and for ACVR2 such a region may occur
upwards of 900 bp from the TSS.
We are mindful that the total number of MSS patients with
ACVR2 loss that were investigated in this study is not large,
underscoring that this is a relatively infrequent event [15]. We did
notintend todeterminetheoverall frequenciesofsuch events,butto
show an alternative mechanism of ACVR2 protein loss in MSS
colon cancers. Of 51 primary, population-based MSS tumor
samples, 7 showed loss of ACVR2 expression. In keeping with the
51 subjects being randomly drawn from the cohort, between 7%
and 21% of MSS tumors in the population should show similar loss
of ACVR2 expression with 95% confidence(Clopper-Pearson exact
confidenceinterval). Increasingthesample size to 77revealed lossof
ACVR2in12/77or16%andastatisticallysignificantcorrelationof
loss of ACVR2 with increased tumor size. Further, genomic subtype
analysis revealed that LOH at ACVR2 was associated with the CIN
phenotype, while ACVR2 hypermethylation correlated with the
CIMP phenotype. While these categorizations allow attribution of
loss of ACVR2 expression to promoter hypermethylation and/or
chromosomal instability as a mechanism in MSS cancers,
alternative mechanisms such as histone modification and/or
microRNAs may be at play, particularly in the LOH negative/
methylation negative cancers. Our data however, show a significant
correlation between loss of ACVR2 expression and LOH/
epigenetic silencing. Thus we provide evidence for the existence
Table 3. ACVR2 expression and mechanisms for loss of expression in colon cancer cell lines.
MSI Status ACVR2 (WT=A8) ACVR2 methylation ACVR2 mRNA ACVR2 protein
CaCo2 MSS wildtype partial present present
FET MSS wildtype partial present present
HCT116 MSI A7 partial present loss
HT29 MSS wildtype full loss loss
SW48 MSI A7/8 partial present present
RKO MSI A6/8 partial present present
Using colon cancers cells with different microsatellite instability backgrounds, we confirm wild type A8 exon 10 polyadenine tract in all MSS colon cancer cell lines. As
previously published, the MSI colon cancer cell line HTC116 harbors biallelic A8 to A7 frameshifts, leading to loss of full length ACVR2 protein [12]. Two MSI cell lines,
SW48 and RKO, harbor mono-allelic mutations with no effect on ACVR2 gene expression. The MSS colon cancer cell line HT29 revealed full ACVR2 promoter
hypermethylation, akin to ACVR2 loss in primary human tumors, and was associated with loss of ACVR2 mRNA and protein.
doi:10.1371/journal.pone.0008308.t003
Table 4. Loss of ACVR2 expression is associated with larger
tumor volume.
ACVR2
Expression
Loss of ACVR2
Expression P-value
Age, mean 63.60 61.82 0.620
Gender
Male, n, (%) 31/58 (53) 4/11 (36) 0.299
Female, n, (%) 27/58 (47) 7/11 (64)
Race
White, n, (%) 22/58 (38) 7/11 (64) 0.113
Black, n, (%) 36/58 (62) 4/11 (36)
Tumor Volume n=40 n=6
Mean 16.11 35.73 0.024*
Median 8.70 28.73
Tumor Stage n=49 n=10
Duke A & B, n, (%) 41/49 (84) 10/10 (100) 0.169
Duke C & D, n, (%) 8/49 (16) 0/10 (0)
Grade n=55 n=10
Well & Moderately
Differentiated, n, (%)
50/55 (91) 8/10 (80) 0.306
Poorly
Differentiated, n, (%)
5/55 (9) 2/10 (20)
ACVR2-expressing and non-expressing cancers were assessed for correlation of
ACVR2 status with age, gender, race, tumor volume, stage and a grade.
*p ,0.05.
doi:10.1371/journal.pone.0008308.t004
ACVR2 in MSS Colon Cancers
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ACVR2 in colon cancer and identify a cell model for epigenetic
silencing of ACVR2. The full clinical impact of this data will require
further confirmation in future studies with larger patient samples.
In conclusion, loss of ACVR2, ACVR1 and pSMAD2
expression occurs in a subset of MSS tumors, and the evidence
supports that this results in abrogation of the normal growth
suppressive activity of activin signaling. Decreased pSMAD2 is
commonly associated with wild type ACVR2 and ACVR1.
Mechanisms for ACVR2 loss include LOH at ACVR2 and ACVR2
promoter hypermethylation between nucleotides 21297 and
2958, which are associated with CIN and CIMP phenotypes,
respectively. Loss of ACVR2 is associated with increased tumor
size. Therefore, activin signaling can be inactivated by distinctive
mechanisms in MSI and MSS colon cancers, suggesting the
importance of this pathway in controlling colonocyte growth.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of North Carolina
hospitals. All patients provided written informed consent for the
collection of samples as part of the under IRB approval as part of
the North Carolina Colorectal Cancer Study (NCCCS) see below.
Analysis as part of this study was completely de-identified and no
identifying information was available to the PI, making this study
exempt from a separate consent.
Patient Samples
Sporadic colon tumors were prospectively collected under IRB
approval as part of the North Carolina Colorectal Cancer Study
(NCCCS), a population-based, case-control study comprising 503
patients [15,16]. Microsatellite analysis was performed from
paraffin-embedded tissue as previously described [2], segregating
the cohort into 54 MSI-H, and 449 MSS/MSI-L patients. For this
study, 51 MSS patient samples with ample tumor and normal
tissue were randomly selected.
Cell Lines
The MSI colon cancer cells lines HCT116, SW48, DLD1,
HCA7, HCT15, LoVo, LS174T, SNU175, SNU407, SW48, and
RKO, as well as the MSS colon cancer cell lines CaCo2, HT29,
SNU81, SNU503, SW480, and T84 were maintained in Iscove’s
Modified Dulbecco’s Medium (Invitrogen Corporation, Carlsbad,
CA) and FET were maintained in F12/Dulbeco’s Modified Eagles
Medium at conditions previously described [12]. All cell lines are
available from ATCC except for FET (kind gift of Michael
Brattain, Medical College of Ohio, Toledo, OH) [21].
Tissue Microdissection, DNA Extraction, and RNA
Extraction
DNA from the formalin-fixed, paraffin-embedded material was
extracted following microdissection using the Takara DEXPAT kit
(Takara Bio Inc., Japan). Genomic DNA from cells lines was
obtained using QIAamp DNA mini kit (Qiagen, Valencia, CA).
RNA from cell lines was obtained using the TRIzol reagent (Life
Technologies Inc. Carlsbad, CA).
Antibodies
Rabbit anti-TyrGly mACVR2 (482–494) (generous gift from W.
Vale, Salk Institute), with its target epitope in the C-terminus
region of ACVR2 (beyond the resulting truncation from frameshift
in exon 10) was used for immunohistochemistry as previously
described [2,12]; rabbit anti-TyrGly ACVR1 (474–494) was used
at 1:800; pSMAD2 (Cell Signaling) at 1:250; total SMAD2
(Epitomics) at 1:400; and TGBR2–C16 (Santa Cruz) at 1:300.
Immunohistochemistry for ACVR1, ACVR2, pSMAD2,
TGFBR2 and SMAD2 Protein Expression
Immunohistochemistry was performed as described previously
[2]. Staining was grouped into loss or 0 (absence or significant
decrease as compared to adjacent normal tissue), reduced or 1+
(subtle decrease as compared to adjacent normal tissue),
unchanged or 2+ (no change as compared to adjacent normal
tissue), and increased or 3+ (increase as compared to adjacent
normal tissue). Three independent investigators blindly scored all
slides. All three investigators had to be in agreement for a tumor to
be called 0 or loss of expression.
Loss of Heterozygosity (LOH) Analysis
Assessment of LOH at the ACVR2 and ACVR1 loci was
performed as previously described [22] utilizing 2 microsatellite
markers (D2S1353 and D2S1399) flanking ACVR2 [19] as well as
an intragenic marker for ACVR1 (D2S2686) (see Table S1).
CIN Analysis
Analysis for CIN was performed as previously described [23].
Briefly, forward oligonucleotide primers were fluorescent-labeled
with FAM at the 59end (Applied Biosystems) and a set of 6
polymorphic microsatellite markers (D5S346, D5S409 D17S261
D17S250 D18S81, D18S91, and D18S69) (see Table S1) was used
to determine LOH at chromosome 5q, 17q and 18q. PCR
amplifications were performed on genomic DNA templates from
both tumor and corresponding normal tissues. The amplified
fluorescent PCR products were electrophoresed on an ABI PRISM
3100 Avant Genetic analyzer and analyzed by GeneMapper
fragment analysis software (Applied Biosystems). When comparing
the signal intensities of individual markers in tumor DNA with that
of the corresponding normal DNA, a reduction of at least 40% in
the signal intensity was considered indicative of LOH.
Bisulfite Modification, Methylation Specific PCR (MSP)
and Bisulfite Sequencing
DNA from matched colon cancer tissues and corresponding
normal mucosa from CRC patients as well as DNA from colon
cancer cell lines underwent bisulfite modification as described
previously [24].
For methylation analysis, we first identified the tentative CpG
islands in the promoter region of the ACVR2 gene based upon
mapping analysis using CpG island search program (http://www.
uscnorris.com/cpgislands/cpg.cgi). Accordingly, we designed mul-
tiple primer sets for MSP and bisulfite sequencing that spanned the
entire ACVR2 promoter region, including part of exon 1, to
determine methylation density across all CpG dinucleotides with
methylation specific primers (see Table S1). Bisulfite sequencing
was initially performed on colon cancer cell lines as it allowed
amplification of larger amplicons, and helped determine critical
regions of promoter methylation that were subsequently PCR
amplified in the clinical samples.
ACVR2 Genotyping
Three hotspots in conserved regions of the kinase domain of
ACVR2 [25], homologous to the previously identified point mutations
in TGFBR2 [ 4 ]a sw e l la st h ec o d i n gA 8 microsatellites of ACVR2 in
ACVR2 in MSS Colon Cancers
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followed by sequencing as previously described [2]. All exons of
ACVR2 were amplified from genomic DNA extracted from select
ACVR2 expressing and non-expressing colon cancer cell lines using
specific primers (see Table S1) and subjected to sequencing using the
DNA SequencingShared Resource, UCSD Cancer Center.Any new
mutations were to be deposited to GenBank.
Quantitative Expression of ACVR2 mRNA
To detect the amplification of ACVR2 in colon cancer cells, we
performed a quantitative polymerase-chain reaction. Briefly, all 17
colon cancer cell lines were grown to 60% confluence. RNA was
extracted using a Trizol-based protocol. The concentration of
RNA dissolved in DEPC-treated water was assessed using a
Beckman-Coulter DU640B spectrophotometer (Beckman-Coulter,
Fullerton, CA). We performed RT-PCR using an oligo dT for
incubation at 37uC to generate cDNA as previously described
[12]. Then, quantitative PCR was carried out using specific
primers for exon 10 (see Table S1) Templates from each cell line
were prepared in triplicate per target gene as 10 mL reactions
(40 ng template, 2X Mesa Green qPCR MasterMix for SYBR
assay, 100X forward and reverse primers). Templates were plated
on fast optical 96-well plate (Applied Biosystems, Foster City, CA)
and spun for 2 minutes at 2000 rpm. Results were observed and
analyzed on the StepOnePlus Real-Time PCR System (Applied
Biosystems, Foster City, CA). GAPDH mRNA amplification was
performed in parallel (59- CATGTTCGTCATGGGTGT-
GAACCA-39,5 9-AGTGATGGCATGGACTGTGGTCAT-39)
to obtain a normalized ACVR2-GAPDH after the relative
expression of each gene was calculated using standard curves.
Immunoprecipitation (IP)
To detect presence of ACVR2 in the colon cancer cell lines, we
performed immunoprecipitation with ACVR2 followed by
Western blotting as previously described [12]. Then, a subset of
HT29 cells was either treated with the demethylating agent 5-Aza
(Sigma) for 72 hours or vehicle prior to lysis and assessment of
ACVR2 expression.
Statistical Analysis
Analysis was performed with the help of the UCSD Moores
Cancer Center Biostatistics Core (K.M.) applying Fisher’s exact
test and Student’s t-test with a p value of ,0.05 indicating
statistical significance. Further, Clopper-Pearson exact confidence
interval was used to determine the 95% confidence interval.
Supporting Information
Table S1 Specific primers used in LOH analysis, ACVR2
genotyping as well as ACVR2 promoter bisulfite sequencing. F
denotes forward primer, R denotes reverse primer; U denotes
unmethylated and M methylated.
Found at: doi:10.1371/journal.pone.0008308.s001 (0.09 MB
DOC)
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